Comparing Bariatric Surgery, Semaglutide, and Tirzepatide for Obesity Treatment

Obesity is a global health crisis, often leading to severe comorbidities like type 2 diabetes, hypertension, and cardiovascular disease. While bariatric surgery has long been considered the most effective intervention for significant and sustained weight loss, newer pharmacological agents like Semaglutide and Tirzepatide have demonstrated remarkable efficacy. This upcoming clinical trial aims to directly compare the long-term efficacy and safety of these leading medical therapies against bariatric surgery.

As this study is currently RECRUITING and has not yet begun, there are no findings to report. However, the trial is designed to assess several critical outcomes. It will primarily evaluate the percentage total body weight loss at 12 and 24 months post-intervention across all three groups. Researchers will also measure the remission rates of obesity-related comorbidities, such as type 2 diabetes and hypertension, and monitor adverse event profiles and quality of life metrics. The overarching goal is to determine if Semaglutide or Tirzepatide can achieve comparable or superior long-term weight loss and comorbidity resolution compared to bariatric surgery, while also assessing their safety and tolerability over time.